Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 30;18(5):2081024.
doi: 10.1080/21645515.2022.2081024. Epub 2022 Jun 10.

Safety and clinical efficacy of human rabies immunoglobulin in post exposure prophylaxis for category III animal exposures

Ravish S Haradanhalli  1 , Nidhi Fotedar  1 , Nitu Kumari  2 , D H Ashwath Narayana  1
Affiliations

Safety and clinical efficacy of human rabies immunoglobulin in post exposure prophylaxis for category III animal exposures

Ravish S Haradanhalli et al. Hum Vaccin Immunother. .

Abstract

The human rabies immunoglobulin (HRIG) is a life-saving immune biological essential for all category III animal exposures. It provides neutralizing antibodies at the site of exposure until the body can produce vaccine-mediated antibodies. We conducted this study to determine the safety and clinical efficacy of an HRIG being used presently for post-exposure prophylaxis (PEP) and to strengthen the existing evidence for its further usage. We conducted a prospective cohort study in 123 subjects with category III animal exposures at the KIMS Hospital and Research Center, Bangalore, India. Post-exposure prophylaxis (PEP) with wound toilet, a single application of HRIG, and a full course of anti-rabies vaccination were provided to all the study subjects. The volume of HRIG was calculated according to the body weight, and all the wounds were infiltrated as was anatomically feasible. All the study subjects were followed up for immediate and delayed adverse events (AE), both local and systemic. Subsequently, all the subjects were followed up for 6 months to demonstrate the clinical efficacy of PEP. The incidence of AEs was 11.4% including local pain, erythema, itching, headache, body ache, fever, and malaise. All AEs were mild and subsided without any complications. All the study subjects were healthy and alive after 6 months following the administration of HRIG, along with a full course of anti-rabies vaccine. Our study provides evidence of safety and clinical efficacy of HRIG for category III animal exposures and supports its continued usage.

Keywords: Safety; category III animal exposures; clinical efficacy; human rabies immunoglobulin; post exposure prophylaxis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

References

    1. WHO Expert Consultation on Rabies . Third report, technical report series 1012. Geneva: World Health Organization; 2018.
    1. Tarantola A. Four thousand years of concepts relating to rabies in animals and humans, its prevention and its cure. Trop Med Infect Dis. 2017;2(2):1. doi: 10.3390/tropicalmed2020005. - DOI - PMC - PubMed
    1. World Health Organization . WHO South East Asia Region: Strategic framework for elimination of human rabies transmitted by dogs in the South–East Asia region. Regional Office for South East Asia, World Health Organization; 2012.
    1. Knobel DL, Cleaveland S, Coleman PG, Fèvre EM, Meltzer MI, Miranda ME, Shaw A, Zinsstag J, Meslin F-X. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005;83(5):3608. doi: 10.1590/S0042-96862005000500012. - DOI - PMC - PubMed
    1. World Health Organization . Weekly epidemiological record. Rabies Vaccines: WHO position paper No. 16. Wkly Epidemiol Rec 2018;93:201–5.

Publication types